Global Lung Cancer Drugs Market by Disease (Non-Small Cell Lung Cancer, Small Cell Lung cancer), Molecule (Biologics, Small Molecules), Distribution Channel - Forecast 2024-2030- Product Image

Sale

Global Lung Cancer Drugs Market by Disease (Non-Small Cell Lung Cancer, Small Cell Lung cancer), Molecule (Biologics, Small Molecules), Distribution Channel - Forecast 2024-2030

Report
186 Pages
March 2024
Region: Global
360iResearch™
ID: 4896738

UP TO €851EUR$875USD£729GBP OFF until Dec 31^st 2024

The Lung Cancer Drugs Market size was estimated at USD 24.76 billion in 2023, USD 26.98 billion in 2024, and is expected to grow at a CAGR of 9.06% to reach USD 45.45 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lung Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lung Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly & Company Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd.

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease
- Non-Small Cell Lung Cancer
- Small Cell Lung cancer
Molecule
- Biologics
- Small Molecules
Distribution Channel
- Offline
- Online

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Lung Cancer Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lung Cancer Drugs Market?
What are the technology trends and regulatory frameworks in the Lung Cancer Drugs Market?
What is the market share of the leading vendors in the Lung Cancer Drugs Market?
Which modes and strategic moves are suitable for entering the Lung Cancer Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Lung Cancer Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising cases and incidences of lung cancer
5.1.1.2. Growing demand for the targeted therapies by consumers
5.1.1.3. Increase in the number of smokers across the globe
5.1.1.4. Favorable government support to control lung cancer
5.1.2. Restraints
5.1.2.1. Side effects of lung cancer drugs
5.1.3. Opportunities
5.1.3.1. Ongoing research activities in the lung cancer treatments
5.1.3.2. Technological advancement in the fields of novel drugs
5.1.4. Challenges
5.1.4.1. Availability of biologics & targeted therapies and high cost of lung cancer treatments
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Lung Cancer Drugs Market, by Disease

6.1. Introduction
6.2. Non-Small Cell Lung Cancer
6.3. Small Cell Lung cancer

7. Lung Cancer Drugs Market, by Molecule

7.1. Introduction
7.2. Biologics
7.3. Small Molecules

8. Lung Cancer Drugs Market, by Distribution Channel

8.1. Introduction
8.2. Offline
8.3. Online

9. Americas Lung Cancer Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Lung Cancer Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Lung Cancer Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AstraZeneca PLC
13.1.3. Boehringer Ingelheim GmbH
13.1.4. Bristol-Myers Squibb Company
13.1.5. Eli Lilly & Company Ltd.
13.1.6. F. Hoffmann-La Roche AG
13.1.7. GlaxoSmithKline PLC
13.1.8. Incyte Corporation
13.1.9. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
13.1.10. Johnson & Johnson Services, Inc.
13.1.11. Merck & Co., Inc.
13.1.12. Novartis AG
13.1.13. Pfizer, Inc.
13.1.14. Sanofi S.A.
13.1.15. Takeda Pharmaceutical Co. Ltd.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. LUNG CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. LUNG CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LUNG CANCER DRUGS MARKET DYNAMICS
FIGURE 7. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 8. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2023 VS 2030 (%)
FIGURE 10. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 6. LUNG CANCER DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 9. LUNG CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 12. LUNG CANCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. LUNG CANCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 25. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 26. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 28. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 29. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 42. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 43. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 45. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 46. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 51. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 52. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 69. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 70. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 79. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 80. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 82. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 83. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 85. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 86. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 88. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 89. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 97. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 98. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 106. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 107. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 109. POLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 110. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 112. QATAR LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 113. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 124. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 133. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 134. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 142. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 143. LUNG CANCER DRUGS MARKET LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly & Company Ltd.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Incyte Corporation
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Takeda Pharmaceutical Co. Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	186
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 26.98 Billion
Forecasted Market Value ( USD ) by 2030	$ 45.45 Billion
Compound Annual Growth Rate	9.0%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3283EUR$3,374USD£2,812GBP €3648EUR$3,749USD£3,125GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4159EUR$4,274USD£3,562GBP €4621EUR$4,749USD£3,958GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5034EUR$5,174USD£4,313GBP €5594EUR$5,749USD£4,792GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5910EUR$6,074USD£5,063GBP €6567EUR$6,749USD£5,625GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7661EUR$7,874USD£6,563GBP €8513EUR$8,749USD£7,292GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Lung Cancer Therapeutics Market by Molecules (Biologics, Small Molecules), Disease (NSCLC, SCLC), Cancer Type, Therapy, Distribution - Forecast 2024-2030

Global Non-small Cell Lung Cancer Therapeutics Market by Cancer Type (Adenocarcinoma, Large Cell Carcinoma, Squamous Cell Carcinoma), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites), Distribution Channel - Forecast 2024-2030

Global Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities (Chemotherapy, Combination Therapies, Immunotherapy), Drug Type (Atezolizumab, Durvalumab, Etoposide), Route of Administration, Distribution Channel - Forecast 2024-2030

Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Her2+ Non Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast - 2032

About the Lung Cancer Drugs Market